Abu Dhabi Global Healthcare Week Partners with Digital Health New York to Boost Digital Health Ecosystem

By HEOR Staff Writer

October 8, 2023

Unifying Efforts for Digital Health Ecosystem Globally

Abu Dhabi Global Healthcare Week (ADGHW) has partnered with Digital Health New York (DHNY) to enhance the global digital health ecosystem. The Memorandum of Understanding (MoU), signed on October 4, 2023, aims to promote collaboration, innovation, long-term investment, and knowledge exchange in the digital health sector.

The two-year partnership will focus on developing research and innovation in digital health, enhancing credibility in science, and providing access to subject-matter experts through open dialogue.

Tackling Global Healthcare Challenges through Digital Tools

The partnership comes at a time when global healthcare demands require collaboration and access to digital tools. Both ADGHW and DHNY are committed to supporting ongoing research and development initiatives, particularly in genomics, preventative and predictive medicine.

H.E. Dr. Ahmed Alkhazraji, Executive Director, Strategy and Policy at the Department of Health – Abu Dhabi and Bunny Ellerin, Co-Founder & CEO, DHNY, signed the partnership. The collaboration aims to leverage both parties’ rich networks to access long-term investment and forge partnerships in the global digital health arena.

ADGHW and DHNY also emphasise the importance of scientific credibility in the healthcare industry and are joining forces in collaborative research studies and the creation of scientific literature.

Reference url

Recent Posts

Workshop on AI in GMP Manufacturing: Shaping Future Guidance from EMA

By HEOR Staff Writer

May 11, 2026

The European Medicines Agency is convening a two-day multistakeholder workshop to collect expert contributions that will inform the development of Annex 22 guidance on AI in GMP Manufacturing. Date: 30 June – 1 July 2026 Format: Hybrid The event features: ...
Developer Engagement Misalignment: Challenges in Assessing Advanced Therapies
Advanced Therapy Medicinal Products (ATMPs) offer transformative options for rare and previously untreatable conditions, yet their high upfront costs, uncertain durability, and single-arm trial data create major reimbursement barriers. The 2026 pre-proof study by Greco et al. shows that developer...
MEA Adoption Challenges in Advanced Therapy Medicinal Products: Insights and Implications
MEA Adoption Challenges continue to limit the practical use of Managed Entry Agreements for Advanced Therapy Medicinal Products across Europe. The 2026 pre-proof paper by Greco et al. draws on interviews with HTA bodies and payers in England, the Netherlands, and Spain to show that hybrid agreeme...